Serum growth differentiation factor-15 levels in Behçet’s syndrome

Behçet’s syndrome (BS) is a heterogeneous systemic vasculitis characterized by chronic inflammation and immune dysregulation. Growth differentiation factor-15 (GDF-15), a member of the transforming growth factor-β superfamily, has been implicated in chronic inflammatory and immune stress responses. This study aimed to evaluate serum GDF-15 levels in patients with BS and to investigate their relationship with disease activity and clinical parameters. This cross-sectional study included 49 patients diagnosed with BS according to International Study Group criteria, as well as a control group of 33 healthy individuals. Demographic characteristics, clinical features, laboratory parameters, treatments, and disease activity scores were recorded. Serum GDF-15 levels were measured using a commercial enzyme-linked immunosorbent assay. Statistical analyses were performed to compare groups and to evaluate associations between GDF-15 levels and clinical and laboratory variables. In the unadjusted comparison, serum GDF-15 levels were significantly higher in patients with BS than in controls ( P = .016). However, GDF-15 levels were not associated with disease activity scores. In multivariable logistic regression adjusting for sex and BMI, GDF-15 was no longer an independent predictor of BS (adjusted P = .53), whereas sex (OR = 5.61, P = .006) and BMI (OR = 0.86, P = .024) remained independently associated with the group, indicating that the unadjusted GDF-15 difference largely reflects demographic confounding rather than a disease-specific effect. No significant correlations were observed between GDF-15 levels and classical acute-phase reactants. This study underscores the importance of recognizing negative biomarker findings to prevent overinterpretation of biomarker utility. Although serum GDF-15 levels were higher in patients with BS in the unadjusted comparison, this difference was no longer statistically significant after adjustment for sex and BMI. GDF-15 levels were also not associated with disease activity, limiting their utility as a disease-specific biomarker. Further longitudinal studies are needed.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-09-11
DOI
https://doi.org/10.1097/md.0000000000050439
Primary Topic
GDF15 and Related Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Serum growth differentiation factor-15 levels in Behçet’s syndrome

Sezgin Zontul, Mesude Seda Aydoğdu, Zeynep Kaya, Servet Yolbaş et al.
Medicine
GDF15 and Related Biomarkers
article

Serum growth differentiation factor-15 levels in Behçet’s syndrome

Sezgin Zontul, Mesude Seda Aydoğdu, Zeynep Kaya, Servet Yolbaş, Cihat Uçar, Elif İnanç
article en

Abstract

Behçet’s syndrome (BS) is a heterogeneous systemic vasculitis characterized by chronic inflammation and immune dysregulation. Growth differentiation factor-15 (GDF-15), a member of the transforming growth factor-β superfamily, has been implicated in chronic inflammatory and immune stress responses. This study aimed to evaluate serum GDF-15 levels in patients with BS and to investigate their relationship with disease activity and clinical parameters. This cross-sectional study included 49 patients diagnosed with BS according to International Study Group criteria, as well as a control group of 33 healthy individuals. Demographic characteristics, clinical features, laboratory parameters, treatments, and disease activity scores were recorded. Serum GDF-15 levels were measured using a commercial enzyme-linked immunosorbent assay. Statistical analyses were performed to compare groups and to evaluate associations between GDF-15 levels and clinical and laboratory variables. In the unadjusted comparison, serum GDF-15 levels were significantly higher in patients with BS than in controls ( P = .016). However, GDF-15 levels were not associated with disease activity scores. In multivariable logistic regression adjusting for sex and BMI, GDF-15 was no longer an independent predictor of BS (adjusted P = .53), whereas sex (OR = 5.61, P = .006) and BMI (OR = 0.86, P = .024) remained independently associated with the group, indicating that the unadjusted GDF-15 difference largely reflects demographic confounding rather than a disease-specific effect. No significant correlations were observed between GDF-15 levels and classical acute-phase reactants. This study underscores the importance of recognizing negative biomarker findings to prevent overinterpretation of biomarker utility. Although serum GDF-15 levels were higher in patients with BS in the unadjusted comparison, this difference was no longer statistically significant after adjustment for sex and BMI. GDF-15 levels were also not associated with disease activity, limiting their utility as a disease-specific biomarker. Further longitudinal studies are needed.

MedicineVol. 105(37)
Inonu University (TR), Malatya Turgut Özal Üniversitesi (TR), Istanbul Eye Hospital (TR), Turgut Özal University (TR)
Good health and well-being
Openalex Percentile: Top 9%
GDF15 and Related Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.